Price: $14.7000
$0.01
0.068%
|
Day's High:
| $14.76
| Week Perf:
| 0.48 %
|
Day's Low: |
$ 14.63 |
30 Day Perf: |
0.62 % |
Volume (M): |
2,389 |
52 Wk High: |
$ 14.76 |
Volume (M$): |
$ 35,124 |
52 Wk Avg: |
$14.60 |
Open: |
$14.71 |
52 Wk Low: |
$14.54 |
|
|
Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
- |
Employees |
1 |
Revenues (TTM) (Millions $) |
223 |
Net Income (TTM) (Millions $) |
0 |
Cash Flow (TTM) (Millions $) |
119 |
Capital Exp. (TTM) (Millions $) |
1 |
Amryt Pharma Plc
Amryt Pharma Plc is a biopharmaceutical company based in Dublin, Ireland, with a focus on developing treatments for rare and orphan diseases. The company was founded in 2015 and has since then been dedicated to pursuing innovative treatments for diseases that are often overlooked by larger pharmaceutical companies.
The company's main focus is on developing treatments for a range of diseases, including epidermolysis bullosa, acromegaly, and Cushing's syndrome, which are all rare or orphan diseases with limited treatment options available. Amryt Pharma Plc has a global presence, with offices in Europe and the United States, from where they have been able to make significant progress in the development of important new drugs.
Amryt Pharma Plc operates through three main subsidiaries: Amryt Healthcare, a commercial operation that focuses on launching and distributing high-quality medicines in Europe; Amryt Pharma US, the company's recently established U.S. subsidiary that is responsible for clinical development, regulatory approval, and commercial launch of products in the United States; and Cutanea Life Sciences, which focuses on developing treatments for rare dermatological diseases.
The company has a number of proprietary products in its portfolio, including Lojuxta, a treatment for adult patients with homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder that causes high levels of bad cholesterol in the blood. Lojuxta has been approved for marketing by the European Medicines Agency (EMA) since 2013 and is available in more than 20 countries around the world.
Another important product in Amryt Pharma Plc's portfolio is Myalepta, a treatment for generalized lipodystrophy, a rare disorder that causes the loss of fat tissue throughout the body. Myalepta has been approved for use in Europe since 2014 and is currently under review by the U.S. Food and Drug Administration (FDA).
Recently, the company has been making progress in the development of a treatment for epidermolysis bullosa (EB), a rare genetic disorder that causes the skin to blister and slough off easily. This debilitating condition has limited treatment options and no cure, making Amryt Pharma Plc's progress in this area all the more important.
Overall, Amryt Pharma Plc is a company with a clear mission and a strong focus on developing innovative treatments for rare and orphan diseases. The company's proprietary products, global presence, and commitment to research and development position it well for continued growth and success in the biopharmaceutical industry.
Company Address: Dept 920a 196 High Road London 0
Company Phone Number: 1518 0200 Stock Exchange / Ticker: NASDAQ AMYT
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Leap Therapeutics Inc
Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million. Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.
|
Xbiotech Inc
Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects. One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.
|
Acurx Pharmaceuticals Inc
Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average. The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.
|
Soligenix Inc
As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year. In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance. Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.
|
Eterna Therapeutics Inc
In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products. Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.
|
Per Share |
Current |
Earnings (TTM) |
0 $ |
Revenues (TTM) |
-
|
Cash Flow (TTM) |
- |
Cash |
-
|
Book Value |
-
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
0 $
|
Revenues (TTM) |
- |
Cash Flow (TTM) |
- |
Cash |
-
|
Book Value |
- |
Dividend (TTM) |
0 $ |
|
|
|
|